Ocular Therapeutix (NASDAQ: OCUL) insider transactions
In the twelve months to 10 November 2026, executives and directors of Ocular Therapeutix reported 29 open-market sales of 368,121 shares ($3.3m) and 1 open-market purchase of 60,229 shares ($461,354), by 9 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 6 November 2026 | Sherif Riad | Director | Grant or award | +28,000 | — | 28,000 | Form 4 |
| 5 November 2026 | Saroj Namrata | Chief Business Officer | Open-market sale, 10b5-1 plan | −35,370 | $6.55 | 220,522 | Form 4 |
| 8 October 2026 | Anderman Todd | Chief Legal Officer | Open-market sale, 10b5-1 plan | −11,984 | $7.29 | 140,484 | Form 4 |
| 2 October 2026 | Heier Jeffrey S. | Chief Scientific Officer | Open-market sale, 10b5-1 plan | −10,869 | $7.05 | 307,457 | Form 4 |
| 2 October 2026 | Kaiser Peter | Chief Development Officer | Open-market sale, 10b5-1 plan | −9,990 | $7.05 | 254,388 | Form 4 |
| 31 August 2026 | Notman Donald | Chief Operating Officer | Open-market sale | −1,099 | $10.24 | 366,529 | Form 4 |
| 25 August 2026 | Dugel Pravin | See Remarks | Gift, 10b5-1 plan | −50,092 | — | 0 | Form 4 |
| 25 August 2026 | Dugel Pravin | See Remarks | Gift, 10b5-1 plan | +50,092 | — | 744,903 | Form 4 |
| 24 August 2026 | Dugel Pravin | See Remarks | Open-market sale, 10b5-1 plan | −21,649 | $10.77 | 2,525,429 | Form 4 |
| 24 August 2026 | Heier Jeffrey S. | Chief Scientific Officer | Open-market sale, 10b5-1 plan | −3,296 | $10.78 | 318,326 | Form 4 |
| 24 August 2026 | Nayak Sanjay | Chief Strategy Officer | Open-market sale, 10b5-1 plan | −1,897 | $10.78 | 326,898 | Form 4 |
| 24 August 2026 | Kaiser Peter | Chief Development Officer | Open-market sale, 10b5-1 plan | −3,035 | $10.77 | 264,378 | Form 4 |
| 16 June 2026 | Dugel Pravin | See Remarks | Gift | −50,092 | — | 2,547,078 | Form 4 |
| 16 June 2026 | Dugel Pravin | See Remarks | Gift | +50,092 | — | 50,092 | Form 4 |
| 10 June 2026 | Williams Leslie J. | Director | Grant or award | +14,000 | — | 65,433 | Form 4 |
| 10 June 2026 | Raines Merilee | Director | Grant or award | +14,000 | — | 60,933 | Form 4 |
| 10 June 2026 | Lindstrom Richard L MD | Director | Grant or award | +14,000 | — | 260,933 | Form 4 |
| 10 June 2026 | Hong Seung Suh | Director | Grant or award | +14,000 | — | 60,933 | Form 4 |
| 10 June 2026 | Robins Jason Shand | Chief Financial Officer | Grant or award | +15,441 | — | 68,097 | Form 4 |
| 10 June 2026 | Graves Adrienne L | Director | Grant or award | +14,000 | — | 64,000 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Ocular Therapeutix page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.